Panel Discussion: Defining Success in Antigen Specific Immune Tolerance

• What does true success look like in ASIT – single-dose cures, durable remission, or reduced treatment burden?
• How can the field align on shared clinical benchmarks as we move from preclinical to human data
• What lessons can be drawn from broader immunology approaches, such as B cell depletion, allergy learnings and tolerance induction?
• How do current clinical outcomes compare between targeted tolerance and broader immunoregulatory mechanisms?

Speakers:

Aaron Winkler

Senior Scientific Director, Immune Tolerance Lead, Inflammation and Immunology

Pfizer

Michael Engsig

Chief Executive Officer

Nykode Therapeutics